Zaltrap: new treatment option for metastatic colorectal cancer

on the 1 May 2013

Zaltrap (aflibercept) is licensed for the treatment of metastatic colorectal cancer that is resistant to or has progressed following oxaliplatin therapy, in combination with irinotecan, 5-FU and folinic acid (FOLFIRI).

Zaltrap is administered by intravenous infusion over 1 hour every two weeks and is continued until disease progression or unacceptable toxicity
Zaltrap is administered by intravenous infusion over 1 hour every two weeks and is continued until disease progression or unacceptable toxicity

PHARMACOLOGY 

Aflibercept is a recombinant fusion protein that binds to vascular endothelial growth factor (VEGF) receptors 1 and 2. By binding to these receptors, it reduces the growth of blood vessels that supply tumours with oxygen and nutrients.1

CLINICAL STUDIES

Aflibercept was investigated in a randomised, double-blind trial in 1,226 patients with metastatic colorectal cancer who had previously received oxaliplatin therapy, with or without prior bevacizumab.2

The addition of aflibercept to FOLFIRI significantly improved median survival relative to placebo plus FOLFIRI, from 12.1 months to 13.5 months, respectively. The overall response rate in the aflibercept plus FOLFIRI arm was 19.8% versus 11.1% for placebo plus FOLFIRI (p=0.0001).2

 REFERENCES

  1. Zaltrap Summary of Product Characteristics, February 2013.
  2. Van Cutsem E et al. J Clin Oncol 2012; 30: 3499–506.

View Zaltrap drug record

Further information: Sanofi

Follow MIMS on Twitter

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Twitter  

More from MIMS

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.

Researchers query safety of delaying antibiotics for UTI in elderly

Researchers query safety of delaying antibiotics for UTI in elderly

Delaying or withholding antibiotics for symptoms of...

Blood Glucose Testing Strips and Meters

Blood Glucose Testing Strips and Meters

Compatible test strips for blood glucose meters.